A randomised controlled trial of intravenous magnesium sulphate versus placebo in the management of women with severe pre‐eclampsia
Objective To determine whether the administration of prophylactic intravenous magnesium sulphate reduces the occurrence of eclempsia in women with severe pre‐eclampsia. Design Randomised controlled trial. Setting A tertiary referral obstetric unit. Population Eight hundred and twenty‐two women with...
Gespeichert in:
Veröffentlicht in: | BJOG : an international journal of obstetrics and gynaecology 1998-03, Vol.105 (3), p.300-303 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Objective
To determine whether the administration of prophylactic intravenous magnesium sulphate reduces the occurrence of eclempsia in women with severe pre‐eclampsia.
Design
Randomised controlled trial.
Setting
A tertiary referral obstetric unit.
Population
Eight hundred and twenty‐two women with severe pre‐eclampsia requiring termination of pregnancy by induction of labour or caesarean section.
Methods
The women were randomised to receive either placebo (saline) or magnesium sulphate intravenously. The investigators were blinded to the contents of the pre‐mixed solutions.
Main outcome measure
The occurrence of eclampsia in the two groups.
Results
The data of 699 women were evaluated. Fourteen were withdrawn after randomisation. The overall incidence of eclampsia was 1.8%. Of 345 women who received magnesium sulphate, one developed eclampsia (0.3%); in the placebo group, 11/340 women (3.2%) developed eclampsia (relative risk 0.09; 95% confidence interval 0.01–0.69; P= 0.003).
Conclusion
The use of intravenous magnesium sulphate in the management of women with severe pre‐eclampsia significantly reduced the development of eclampsia. |
---|---|
ISSN: | 1470-0328 0306-5456 1471-0528 1365-215X |
DOI: | 10.1111/j.1471-0528.1998.tb10090.x |